Edition:
United Kingdom

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.74USD
15 Dec 2017
Change (% chg)

$0.04 (+2.35%)
Prev Close
$1.70
Open
$1.71
Day's High
$1.74
Day's Low
$1.70
Volume
20,094
Avg. Vol
38,342
52-wk High
$4.07
52-wk Low
$0.87

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences files for mixed shelf of up to $100 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing.  Full Article

Apricus Biosciences reports Q3 loss per share $0.29
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences Inc provides corporate update and third quarter 2017 financial results.Q3 loss per share $0.29.Apricus Biosciences Inc - ‍as of September 30, 2017, company's cash totaled $8.5 million, compared to $2.1 million as of December 31, 2016​.  Full Article

Apricus Biosciences and certain investors mutually agreed to terminate certain securities purchase agreement
Wednesday, 28 Sep 2016 

Apricus Biosciences Inc : On Sept 27, co and certain investors mutually agreed to terminate certain securities purchase agreement, dated Sept 22 . Entered into a new securities purchase agreement for sale by co of 13.1 million shares of co's common stock, par value $0.001per share .Net proceeds are expected to be approximately $4.2 million and will be used for general corporate and working capital purposes.  Full Article

Apricus Biosciences to issue about 13.1 mln shares at $0.35 per share
Friday, 23 Sep 2016 

Apricus Biosciences Inc [APRI.O] : Apricus Biosciences announces $4.6 million registered direct offering .In connection with offering, will issue about 13.1 million registered shares of common stock at a purchase price of $0.35 per share.  Full Article

Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring
Monday, 15 Aug 2016 

Apricus Biosciences Inc : Company's partner in United Kingdom, has received United Kingdom marketing authorization for Vitaros .Under terms of agreement, Apricus has received a total of $4.5 million in upfront payments from Ferring.  Full Article

Apricus Biosciences announces completion of transfer of Vitaros German marketing authorization to Ferring Pharmaceuticals
Wednesday, 10 Aug 2016 

Apricus Biosciences Inc :Ferring Pharmaceuticals, company's new partner in Germany, has received German marketing authorization for Vitaros.  Full Article

Apricus Biosciences Q2 shr loss $0.05
Thursday, 4 Aug 2016 

Apricus Biosciences Inc : Q2 loss per share $0.05 . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S .Apricus biosciences provides corporate update and second quarter financial results.  Full Article

Apricus Biosciences enters into common stock purchase agreement with Aspire Capital
Wednesday, 6 Jul 2016 

Apricus Biosciences Inc : Apricus Biosciences enters into common stock purchase agreement with Aspire Capital . Aspire Capital will complete an initial purchase of 2.5 million shares of common stock for proceeds of $1.0 million .Aspire Capital to purchase up to $6 million in additional shares of common stock over next 24 months.  Full Article

Apricus Biosciences reports Q1 loss per share of $0.05
Monday, 9 May 2016 

Apricus Biosciences Inc : To continue to reduce operating expenses with goal of achieving reductions of about 30% in 2016, 60% in 2017 compared to 2015 . Apricus biosciences provides corporate update and first quarter financial results . Q1 loss per share $0.05 . Q1 revenue $600,000 versus $500,000 . Q1 revenue view $922,000 -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

Apricus Biosciences Inc announces $10 mln registered direct offering
Wednesday, 13 Jan 2016 

Apricus Biosciences Inc:Announces $10 million registered direct offering.Agreements with certain institutional investors for 11.4 million shares of common stock and warrants to buy up to 5.7 million shares.  Full Article

BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million

* Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing Source text : (http://bit.ly/2gZ2TjB) Further company coverage: